卫生系统实施临床决策支持以优化呼吸道病原体检测组合的使用
本研究评估临床决策支持(CDS)工具对呼吸道病原体检测组合(RPP)使用及试剂成本的影响。CDS通过默认选择小型季节性呼吸道病毒检测组合(SRVP)并提示临床指征,有效减少了RPP的过度使用。
要点
- CDS工具将SRVP设为默认选项,引导临床医生在符合指征时选择针对性检测。
- 诊断管理框架有助于优化多重PCR检测的合理使用,避免不必要的治疗和成本。
核心结论
- 引入CDS工具成功减少了大型呼吸道病原体综合征检测组合的过度使用,鼓励在临床适当时使用SRVP。
研究设计与样本
- 研究回顾了卫生系统内RPP使用情况,并实施CDS工具,该工具提供预批准的临床指征以指导RPP订购或重定向至SRVP。
- 使用2022年1月至2026年1月住院和急诊部门数据,采用中断时间序列分析评估CDS实施前后RPP订购实践的变化。
主要发现
- 回顾性分析显示2022年至2024年RPP订单逐年增加。
- CDS实施后,与实施前相比,RPP订单立即显著下降(-946.70,95%CI:-1,320.2至-573.2)。
临床怎么用
- 在免疫正常患者中,RPP过度使用临床获益有限且可能增加不必要的医院成本,证据支持RPP主要用于重症、免疫抑制或儿科患者。
- 常规病例更适合采用较小的针对性检测,CDS工具可帮助临床医生根据预批准指征选择RPP或SRVP。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Overuse of respiratory pathogen profiles (RPPs) in immunocompetent patients offers limited clinical benefit and may contribute to unnecessary hospital costs. Evidence supports RPP use primarily in severely ill, immunosuppressed, or pediatric patients, while smaller, targeted tests are more appropriate for routine cases . The goal of this study was to evaluate the impact of a clinical decision support (CDS) intervention on RPP utilization and associated reagent costs. We reviewed RPP utilization across the health system and implemented a CDS tool with pre-approved clinical indications to guide appropriate RPP ordering or redirect testing to a smaller seasonal respiratory viral profile (SRVP). Initiation of an RPP order through the CDS tool presented the SRVP as the default, pre-selected option, with users prompted with specific built-in clinical indications before selecting whether to proceed with an RPP or SRVP. Data from inpatient and emergency department settings from January 2022 to January 2026 were used to assess RPP ordering practices pre- and post-CDS implementation. The impact of the CDS implementation on RPP orders was assessed using an interrupted time series analysis. Retrospective analysis revealed a year-to-year increase in RPP orders from 2022 to 2024. After CDS implementation, there was an immediate and significant decrease in RPPs compared to the pre-CDS period (-946.70, 95% CI: -1,320.2 to -573.2). This corresponded to $2.26 million in reagent cost savings. Overall, the introduction of the CDS successfully reduced the overutilization of large respiratory pathogen syndromic panels by encouraging the use of a SRVP when clinically appropriate. IMPORTANCE: Diagnostic stewardship ensures that multiplex molecular assays are used to deliver the right test, for the right patient, at the right time. Through coordinated input from interdisciplinary teams across the diagnostic pathway, stewardship enhances test selection, resource utilization, and interpretation of complex syndromic panels. Although multiplex PCR assays offer high sensitivity, their ability to detect residual nucleic acid from nonviable or colonizing organisms can create diagnostic ambiguity; therefore, it is important to have stewardship frameworks in place to guide appropriate test ordering, timing, and result interpretation and to avoid misinterpreting results. Through integration of laboratory expertise and evidence-based indications, diagnostic stewardship enhances the clinical value of multiplex testing and limits unnecessary treatment and downstream costs.
引用
- Flores EM, Li Y, Reece JT, et al. Health system implementation of clinical decision support to optimize respiratory pathogen profile utilization. J Clin Microbiol. 2026. PMID: 42474392. doi:10.1128/jcm.01909-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。